Analysts at Jefferies Kept the Same their Past ‘Buy’ rating on Shares Haemonetics (NYSE:HAE), Set a $110 TP

June 14, 2018 - By Dolores Ford

Haemonetics Corporation (NYSE:HAE) Logo

Investors sentiment increased to 1.18 in 2018 Q1. Its up 0.07, from 1.11 in 2017Q4. It improved, as 15 investors sold Haemonetics Corporation shares while 81 reduced holdings. 45 funds opened positions while 68 raised stakes. 49.88 million shares or 2.00% less from 50.89 million shares in 2017Q4 were reported.

Virtu Financial Limited Liability Corporation stated it has 8,028 shares. Invesco holds 341,708 shares or 0.01% of its portfolio. Texas Permanent School Fund holds 0.03% in Haemonetics Corporation (NYSE:HAE) or 35,383 shares. Teachers Retirement System Of The State Of Kentucky has invested 0.01% of its portfolio in Haemonetics Corporation (NYSE:HAE). Massachusetts-based Wellington Management Gp Limited Liability Partnership has invested 0.05% in Haemonetics Corporation (NYSE:HAE). Panagora Asset Inc has 792,990 shares for 0.23% of their portfolio. Boston Advisors Ltd has invested 0.07% of its portfolio in Haemonetics Corporation (NYSE:HAE). Swiss Financial Bank accumulated 91,600 shares. Franklin Resource invested in 1.00 million shares. Financial Bank Of New York Mellon holds 663,513 shares. Cibc Asset reported 3,613 shares stake. Systematic Financial Mgmt Limited Partnership invested in 19,980 shares. Fisher Asset Management Ltd Liability Corporation reported 454,115 shares. Jacobs Levy Equity Management stated it has 58,871 shares or 0.07% of all its holdings. Fmr Ltd reported 6,000 shares.

Since January 2, 2018, it had 0 buys, and 9 selling transactions for $1.14 million activity. On Wednesday, June 6 Goldstein Dan sold $360,766 worth of Haemonetics Corporation (NYSE:HAE) or 3,794 shares. 1,941 shares were sold by Simon – Christopher, worth $179,989. KROLL MARK W sold $448,434 worth of stock or 7,118 shares. 214 shares were sold by Scanlan Jacqueline, worth $19,844. Shares for $16,970 were sold by Ryding Neil Mr.. Shares for $39,410 were sold by Burke William P. Mr..

Haemonetics (NYSE:HAE) Rating Reaffirmed

The broker has just set a PT of $110 on Haemonetics (NYSE:HAE) shares. This is 13.99 % from the last stock price. In a note revealed on Thursday morning, Jefferies restate their Buy rating on shares of HAE.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 3 analysts covering Haemonetics Corp (NYSE:HAE), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Haemonetics Corp has $100 highest and $68.0 lowest target. $90’s average target is -6.74% below currents $96.5 stock price. Haemonetics Corp had 8 analyst reports since December 21, 2017 according to SRatingsIntel. The rating was maintained by Morgan Stanley with “Overweight” on Wednesday, February 7. The stock of Haemonetics Corporation (NYSE:HAE) has “Overweight” rating given on Tuesday, January 2 by Morgan Stanley. On Wednesday, May 9 the stock rating was maintained by Morgan Stanley with “Overweight”. Jefferies maintained the shares of HAE in report on Monday, January 8 with “Buy” rating. On Tuesday, January 2 the stock rating was upgraded by Raymond James to “Market Perform”. Jefferies maintained the shares of HAE in report on Thursday, December 21 with “Buy” rating. The rating was maintained by Morgan Stanley with “Buy” on Wednesday, March 28. The company was maintained on Wednesday, February 7 by Jefferies.

The stock increased 5.18% or $4.75 during the last trading session, reaching $96.5. About 784,060 shares traded or 58.43% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 121.77% since June 14, 2017 and is uptrending. It has outperformed by 109.20% the S&P500.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on August, 6. They expect $0.42 EPS, up 27.27 % or $0.09 from last year’s $0.33 per share. HAE’s profit will be $21.93 million for 57.44 P/E if the $0.42 EPS becomes a reality. After $0.43 actual EPS reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -2.33 % negative EPS growth.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $5.04 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It has a 113.53 P/E ratio. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Another recent and important Haemonetics Corporation (NYSE:HAE) news was published by Seekingalpha.com which published an article titled: “S&P indexes swap firms due to shifting market caps; FSB to SmallCap 600” on June 08, 2018.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: